{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower limit and upper limit was not estimable as the concentration was below the lower limit of quantification (LLOQ) of 1.00 nanogram per milliliter (ng/mL).","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, lower limit and upper limit was not estimable as the concentration was below the lower limit of quantification (LLOQ) of 1.00 nanogram per milliliter (ng/mL).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.7","upperLimit":"70.7","value":"70.70"},{"groupId":"OG001","lowerLimit":"0.000","upperLimit":"57.8","value":"13.60"}]}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.6","upperLimit":"70.6","value":"70.60"},{"groupId":"OG001","lowerLimit":"0.000","upperLimit":"49.1","value":"32.70"}]}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.2","upperLimit":"234","value":"36.70"},{"groupId":"OG001","lowerLimit":"0.000","upperLimit":"7.41","value":"0.0000"}]}],"title":"Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Plasma concentration of lenalidomide and pomalidomide was measured in this outcome measure.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with lenalidomide at dose of 15 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 1C: PF-06863135 + Lenalidomide SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with pomalidomide at dose of 4 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG001","title":"Part 1D: PF-06863135 + Pomalidomide SC"}],"paramType":"MEDIAN","populationDescription":"PK Concentration Analysis Set was defined as all participants randomized and treated who had at least 1 measurable PF-06863135 concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (0 hours post dose on Day 1, 8 and 15); Cycle 2 (0 hours on Day 15)","title":"Part 1C and Part 1D: Plasma Concentration of Lenalidomide and Pomalidomide","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter"}